JP7688025B2 - 抗ｃｄ１９抗体及びガンマデルタｔ細胞を含む抗腫瘍併用療法 - Google Patents

抗ｃｄ１９抗体及びガンマデルタｔ細胞を含む抗腫瘍併用療法 Download PDF

Info

Publication number
JP7688025B2
JP7688025B2 JP2022525535A JP2022525535A JP7688025B2 JP 7688025 B2 JP7688025 B2 JP 7688025B2 JP 2022525535 A JP2022525535 A JP 2022525535A JP 2022525535 A JP2022525535 A JP 2022525535A JP 7688025 B2 JP7688025 B2 JP 7688025B2
Authority
JP
Japan
Prior art keywords
cells
antibody
lymphoma
seq
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554324A (ja
JP2022554324A5 (https=
Inventor
エンデル，ヤン
ボクスハンマー，ライナー
プレッチャー，ドミニク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of JP2022554324A publication Critical patent/JP2022554324A/ja
Publication of JP2022554324A5 publication Critical patent/JP2022554324A5/ja
Priority to JP2025085318A priority Critical patent/JP2025134705A/ja
Application granted granted Critical
Publication of JP7688025B2 publication Critical patent/JP7688025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022525535A 2019-10-31 2020-10-30 抗ｃｄ１９抗体及びガンマデルタｔ細胞を含む抗腫瘍併用療法 Active JP7688025B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025085318A JP2025134705A (ja) 2019-10-31 2025-05-22 抗ｃｄ１９抗体及びガンマデルタｔ細胞を含む抗腫瘍併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19206479 2019-10-31
EP19206479.8 2019-10-31
PCT/EP2020/080494 WO2021084063A1 (en) 2019-10-31 2020-10-30 Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025085318A Division JP2025134705A (ja) 2019-10-31 2025-05-22 抗ｃｄ１９抗体及びガンマデルタｔ細胞を含む抗腫瘍併用療法

Publications (3)

Publication Number Publication Date
JP2022554324A JP2022554324A (ja) 2022-12-28
JP2022554324A5 JP2022554324A5 (https=) 2023-11-07
JP7688025B2 true JP7688025B2 (ja) 2025-06-03

Family

ID=68424789

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525535A Active JP7688025B2 (ja) 2019-10-31 2020-10-30 抗ｃｄ１９抗体及びガンマデルタｔ細胞を含む抗腫瘍併用療法
JP2025085318A Pending JP2025134705A (ja) 2019-10-31 2025-05-22 抗ｃｄ１９抗体及びガンマデルタｔ細胞を含む抗腫瘍併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025085318A Pending JP2025134705A (ja) 2019-10-31 2025-05-22 抗ｃｄ１９抗体及びガンマデルタｔ細胞を含む抗腫瘍併用療法

Country Status (23)

Country Link
US (1) US20210130461A1 (https=)
EP (2) EP4706673A2 (https=)
JP (2) JP7688025B2 (https=)
KR (1) KR20220116154A (https=)
CN (1) CN115151565A (https=)
AU (1) AU2020372646A1 (https=)
DK (1) DK4051710T3 (https=)
ES (1) ES3062643T3 (https=)
FI (1) FI4051710T3 (https=)
HR (1) HRP20251630T1 (https=)
IL (1) IL292213A (https=)
LT (1) LT4051710T (https=)
MA (1) MA69251B1 (https=)
MD (1) MD4051710T2 (https=)
MX (1) MX2022005033A (https=)
PH (1) PH12022551009A1 (https=)
PL (1) PL4051710T3 (https=)
PT (1) PT4051710T (https=)
RS (1) RS67602B1 (https=)
SI (1) SI4051710T1 (https=)
SM (1) SMT202600082T1 (https=)
TW (1) TWI883067B (https=)
WO (1) WO2021084063A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR102617497B1 (ko) 2022-09-15 2023-12-27 주식회사 엘지에너지솔루션 음극용 자성 정렬 장치 및 이를 이용한 음극의 제조방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PT2710123T (pt) 2011-05-19 2017-10-13 Inst De Medicina Molecular Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos
AU2015277516A1 (en) * 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
IL297773B2 (en) 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
LT3302550T (lt) * 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
WO2017072367A1 (en) 2015-10-30 2017-05-04 Cancer Research Technology Limited EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS
US11299708B2 (en) 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
WO2018002031A1 (en) 2016-06-27 2018-01-04 Morphosys Ag Anti-cd19 antibody formulations
WO2018081648A2 (en) * 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Blood，2019年11月13日，No.134 (Supplement_1)，p.3801
British J of Haematology，2004年，Vol.126, No.4，pp.583-592
Cancer Immunology, Immunotherapy，2022年，No.71，pp.2829-2836
Cell Discovery，2018年，Vol.4, No.62，pp.1-13
Frontiers in Immunology，2014年，Vol.5, Article 618，pp.1-12
Frontiers in Immunology，2018年，Vol.9, Article 1409，pp.1-10

Also Published As

Publication number Publication date
RS67602B1 (sr) 2026-01-30
SI4051710T1 (sl) 2026-01-30
EP4051710B1 (en) 2025-11-26
LT4051710T (lt) 2026-03-10
MA69251B1 (fr) 2025-12-31
DK4051710T3 (da) 2025-12-15
US20210130461A1 (en) 2021-05-06
PL4051710T3 (pl) 2026-04-20
FI4051710T3 (fi) 2026-01-12
EP4051710A1 (en) 2022-09-07
IL292213A (en) 2022-06-01
TWI883067B (zh) 2025-05-11
WO2021084063A1 (en) 2021-05-06
CA3158984A1 (en) 2021-05-06
TW202131949A (zh) 2021-09-01
AU2020372646A1 (en) 2022-05-12
PT4051710T (pt) 2026-02-09
EP4706673A2 (en) 2026-03-11
KR20220116154A (ko) 2022-08-22
PH12022551009A1 (en) 2023-03-20
HRP20251630T1 (hr) 2026-02-13
JP2022554324A (ja) 2022-12-28
MD4051710T2 (ro) 2026-04-30
JP2025134705A (ja) 2025-09-17
MX2022005033A (es) 2022-09-09
TW202547555A (zh) 2025-12-16
CN115151565A (zh) 2022-10-04
SMT202600082T1 (it) 2026-03-09
ES3062643T3 (en) 2026-04-13

Similar Documents

Publication Publication Date Title
JP7728822B2 (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
JP7688025B2 (ja) 抗ｃｄ１９抗体及びガンマデルタｔ細胞を含む抗腫瘍併用療法
JP2022503685A (ja) 抗ｃｄ１９抗体及びナチュラルキラー細胞を含む、腫瘍を治療する薬学的組み合わせ
US20200262894A1 (en) Strep-tag specific binding proteins and uses thereof
JP2024016200A (ja) キメラ抗原受容体療法のｔ細胞の増殖動態及びその使用
TW202110886A (zh) 共投與抗c-kit及cd47之免疫治療劑的療法
JP2025175307A (ja) 逐次抗ｃｄ１９治療
CN115956088A (zh) 包括抗-CD19抗体和阻断SIRPα-CD47先天免疫检查点的多肽的抗肿瘤组合疗法
US20190169306A1 (en) Cancer and b-cell related disease therapy
JP2025524564A (ja) Ｃｄ１９指向性がん免疫療法の投与レジメン
TWI922280B (zh) 包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法
CA3158984C (en) Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
EA050676B1 (ru) Противоопухолевая комбинированная терапия, включающая антитело к cd19 и гамма-дельта т-клетки
US20240190965A1 (en) Targeting anti-human pd 1h/vista to treat hematologic disorders
AU2020209425B2 (en) Antibody
KR20250060146A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
HK40128442A (zh) 嵌合抗原和t细胞受体及使用的方法
HK40126667A (zh) 嵌合抗原和t细胞受体及使用的方法
HK40118068A (zh) Kir3dl3抑制剂和免疫细胞激活剂
CA3126869A1 (en) Antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241223

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250522

R150 Certificate of patent or registration of utility model

Ref document number: 7688025

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150